OPUS 4 | Search

48 search hits

1 to 20

Sort by

Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab ()

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial ()

Distribution of ACE2, CD147, CD26 and other SARS‐CoV‐2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID‐19 risk factors ()

The skin microbiome as a clinical biomarker in atopic eczema: promises, navigation, and pitfalls ()

Pollen exposure weakens innate defense against respiratory viruses ()

Physical and immunological barrier of human primary nasal epithelial cells from non-allergic and allergic donors ()

Skin pH dependent Staphylococcus aureus abundance as predictor for increasing atopic dermatitis severity ()

Nasal biomarker‐profiles to distinguish between high‐ and low‐symptomatic, non‐allergic and allergic subjects in a natural pollen exposure study [Abstract] ()

The role of pre-existing cross-reactive central memory CD4 T-cells in vaccination with previously unseen Influenza strains ()

Relations between epidermal barrier dysregulation and Staphylococcus species–dominated microbiome dysbiosis in patients with atopic dermatitis ()

Differential T cell response against BK virus regulatory and structural antigens: a viral dynamics modelling approach ()

Pro-inflammatory versus immunomodulatory effects of silver nanoparticles in the lung: the critical role of dose, size and surface modification ()

Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection ()

Considering personalized Interferon-β therapy for COVID-19 ()

From exposure to reaction: panel study on the relationship between pollen exposure and the local and systemic expression of inflammatory parameters ()

Distinct cytokine profiles associated with COVID-19 severity and mortality ()

Tocilizumab in COVID-19 therapy: who benefits, and how? ()

The power and potential of BIOMAP to elucidate host‐microbiome interplay in skin inflammatory diseases ()

Longitudinal effects of SARS-CoV-2 breakthrough infection on imprinting of neutralizing antibody responses ()

Background The impact of the infecting SARS-CoV-2 variant of concern (VOC) and the vaccination status was determined on the magnitude, breadth, and durability of the neutralizing antibody (nAb) profile in a longitudinal multicentre cohort study. Methods 173 vaccinated and 56 non-vaccinated individuals were enrolled after SARS-CoV-2 Alpha, Delta, or Omicron infection and visited four times within 6 months and nAbs were measured for D614G, Alpha, Delta, BA.1, BA.2, BA.5, BQ.1.1, XBB.1.5 and JN.1. Findings Magnitude-breadth-analysis showed enhanced neutralization capacity in vaccinated individuals against multiple VOCs. Longitudinal analysis revealed sustained neutralization magnitude-breadth after antigenically distant Delta or Omicron breakthrough infection (BTI), with triple-vaccinated individuals showing significantly elevated titres and improved breadth. Antigenic mapping and antibody landscaping revealed initial boosting of vaccine-induced WT-specific responses after BTI, a shift in neutralization towards infecting VOCs at peak responses and an immune imprinted bias towards dominating WT immunity in the long-term. Despite that bias, machine-learning models confirmed a sustained shift of the immune-profiles following BTI. Interpretation In summary, our longitudinal analysis revealed delayed and short lived nAb shifts towards the infecting VOC, but an immune imprinted bias towards long-term vaccine induced immunity after BTI. Funding This work was funded by the Bavarian State Ministry of Science and the Arts for the CoVaKo study and the ForCovid project. The funders had no influence on the study design, data analysis or data interpretation.

1 to 20